- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03009214
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
May 7, 2021 updated by: amcure GmbH
A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2).
If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.
Study Overview
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussel, Belgium, 1200
- Cliniques Universitaires Saint Luc
-
Brussels, Belgium, 1000
- Jules Bordet Instiut
-
-
-
-
-
Barcelona, Spain, 08035
- Vall d'Hebron Institute of Oncology (VHIO)
-
Madiedo, Spain, 28050
- START Madrid-CIOCC, Centro Integral Oncológico Clara Campal
-
Málaga, Spain
- Hospital Universitario Virgen de la Victoria
-
Valencia, Spain, 46010
- Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico de Valencia
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
- Institut Catala d'Oncologia, Hospital Duran i Reynals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed and documented, advanced or metastatic, accessible malignant solid tumour of epithelial origin and for which no standard therapy exists or standard therapy has failed.
- Presence of a measurable tumour according to RECIST 1.1. criteria
- At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy (monoclonal antibodies) or cancer immunotherapy (immune checkpoint modulators) or 2 weeks from targeted therapy (receptor tyrosine kinase inhibitors) at time of administration of AMC303.
- Male or female patients, at least 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
- Life expectancy > 12 weeks.
Adequate haematological function defined as
- Absolute neutrophil count (ANC) > 1,500 / µL
- Platelets > 100,000 / µL
- Haemoglobin > 9 g /dL.
Adequate renal function defined as
- Glomerular filtration rate (GFR) ≥ 50 ml/min according to local laboratory standard or
- Serum creatinine < 1.5 mg / dL.
Adequate hepatic function defined as
- Total bilirubin < 1.5x institutional upper limit of normal (ULN)
- AST, ALT ≤ 3x institutional ULN or < 5x institutional ULN if known hepatic metastases
- Alkaline phosphatase < 3x institutional ULN or < 5x institutional ULN if known hepatic metastases.
- Patient may have central nervous system (CNS) involvement if metastases have been treated and are stable at least 4 weeks after completion of radiation therapy and/or surgery. Stable disease is defined as absence of new neurological symptoms, absence of the need for steroid therapy and radiographic confirmation of stable disease. Radiographic confirmation of stable disease 4 weeks after completion of radiation therapy is not required unless indicated by neurological examination.
- All female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. For female participants and female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom) while on study and for 30 days after the last study treatment. For male participants or male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom,) while on study and for three months after the last study treatment.
- Provision of signed Informed Consent prior to any study related procedure being performed
Exclusion Criteria:
- Receipt of any other investigational agent within 28 days prior to first administration of AMC303. Investigational monoclonal antibodies must not be given within 6 weeks before treatment start with AMC303.
- Enrolment in another clinical study with an investigational drug
- Presence of residual toxicities of CTCAE Grade > 1 after prior anti-tumour therapy within 2 weeks of first treatment with AMC303 with the exception of Grade 3 alopecia and infusion site reactions
- Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements
- Anticipation of major surgical procedures within first 4 weeks of first dose
- Pregnancy or breast-feeding as determined by a serum pregnancy test (β-HCG) at screening prior to administration of AMC303 and willingness to father a child or to become pregnant
- Untreated acute infectious disease
- Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS) or is known to be HIV seropositive without AIDS defining disease
- Known chronic hepatitis B or C.
- History of allergic reactions attributed to compounds of similar chemical or biological composition to AMC303.
- Evidence of any other medical conditions that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications
- Previous malignant disease other than the target malignancy to be investigated within the last 5 years with the exception of basal or squamous carcinoma of the skin or cervical carcinoma in situ
- Legal incapacity or limited legal capacity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AMC303
cohorts will receive ascending doses of AMC303 as intravenous infusion Planned doses are: 0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg |
AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of AMC303
Time Frame: 6 months
|
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic properties of AMC303 (Cmax)
Time Frame: 2 days
|
Determine maximum plasma concentration (Cmax)
|
2 days
|
Pharmacokinetic properties of AMC303 (AUC)
Time Frame: 2 days
|
Determine systemic exposure (AUC) after intravenous infusion
|
2 days
|
Pharmacokinetic properties of AMC303 (t1/2)
Time Frame: 2 days
|
Determine half-life of AMC303 after intravenous infusion
|
2 days
|
Response rate of treatment with AMC303 in patients with metastatic solid tumors
Time Frame: 12 months
|
Determination of the complete response (CR) and partial response (PR) in patients treated with AMC303
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Klaus Dembowsky, MD PhD, amcure GmbH
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2016
Primary Completion (Actual)
July 28, 2020
Study Completion (Actual)
May 7, 2021
Study Registration Dates
First Submitted
November 19, 2016
First Submitted That Met QC Criteria
December 31, 2016
First Posted (Estimate)
January 4, 2017
Study Record Updates
Last Update Posted (Actual)
May 10, 2021
Last Update Submitted That Met QC Criteria
May 7, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMC303-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Tumor
-
Daiichi Sankyo Co., Ltd.RecruitingAdvanced Solid Tumor | Malignant Solid TumorUnited States, Japan
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.RecruitingNeoplasms | Solid Tumor | Malignant TumorChina
-
Bristol-Myers SquibbCompletedMalignant Solid TumorUnited States, France, Italy, Australia, Canada, Germany, Netherlands
-
Nektar TherapeuticsCompletedMalignant Solid TumorUnited States, Belgium
-
Medical University of ViennaUnknown
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
Peregrine PharmaceuticalsTerminatedMalignant Solid TumorUnited States
-
Shanghai Acebright Pharmaceuticals Co., Ltd.UnknownMalignant Advanced Solid TumorChina
-
Eli Lilly and CompanyCompletedMalignant Solid TumorUnited States